Stock SGMT SAGIMET BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

Real-time Estimate Cboe BZX
Other stock markets
 03:34:20 2024-05-28 pm EDT 		5-day change 1st Jan Change
5.18 USD +10.21% Intraday chart for Sagimet Biosciences Inc. -0.84% -13.28%
May. 16 Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating MT
May. 15 Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating
MT
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target
MT
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating
MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target
MT
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating
MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating
MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating
MT
TD Cowen Initiates Sagimet Biosciences With Outperform Rating
MT
Goldman Sachs Initiates Sagimet Biosciences at Buy With $33 Price Target
MT
Piper Sandler Initiates Sagimet Biosciences With Overweight Rating, $67 Price Target
MT
JMP Securities Starts Sagimet Biosciences With Market Outperform Rating, $30 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMT Stock
  4. News Sagimet Biosciences Inc.
  5. Analyst Reco.